Neurocrine Biosciences (NBIX) Net Cash Flow Growth (5y) (2015 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.13% |
| Mar 31, 2026 | -36.26% |
| Dec 31, 2025 | 28.95% |
| Sep 30, 2025 | 49.59% |
| Jun 30, 2025 | -21.11% |
| Mar 31, 2025 | -20.31% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | 52.56% |
| Jun 30, 2024 | -41.95% |
| Mar 31, 2024 | 32.65% |
| Dec 31, 2023 | 4.50% |
| Sep 30, 2023 | 35.42% |
| Jun 30, 2023 | 55.71% |
| Mar 31, 2023 | -14.91% |
| Dec 31, 2022 | 42.78% |
| Sep 30, 2022 | 25.98% |
| Jun 30, 2022 | -19.50% |
| Mar 31, 2022 | -28.31% |
| Dec 31, 2021 | 30.68% |
| Sep 30, 2021 | -44.09% |